Trending NewsTrending NewsTop-Rated StocksTop-RatedNASDAQ:ARDX Ardelyx (ARDX) Stock Price, News & Analysis $5.13 +0.74 (+16.86%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$5.07 -0.06 (-1.17%) As of 08/5/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Ardelyx Stock (NASDAQ:ARDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ardelyx alerts:Sign Up Key Stats Today's Range$4.96▼$5.4950-Day Range$3.55▼$5.1352-Week Range$3.21▼$7.18Volume15.83 million shsAverage Volume4.08 million shsMarket Capitalization$1.23 billionP/E RatioN/ADividend YieldN/APrice Target$11.33Consensus RatingBuy Company Overview Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Read More Ardelyx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreARDX MarketRank™: Ardelyx scored higher than 83% of companies evaluated by MarketBeat, and ranked 337th out of 1,836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingArdelyx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageArdelyx has only been the subject of 3 research reports in the past 90 days.Read more about Ardelyx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ardelyx are expected to grow in the coming year, from ($0.18) to $0.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ardelyx is -22.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ardelyx is -22.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArdelyx has a P/B Ratio of 7.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.53% of the outstanding shares of Ardelyx have been sold short.Short Interest Ratio / Days to CoverArdelyx has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Ardelyx has recently decreased by 0.47%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArdelyx does not currently pay a dividend.Dividend GrowthArdelyx does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.32 Percentage of Shares Shorted11.53% of the outstanding shares of Ardelyx have been sold short.Short Interest Ratio / Days to CoverArdelyx has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Ardelyx has recently decreased by 0.47%, indicating that investor sentiment is improving. News and Social Media2.4 / 5News Sentiment0.36 News SentimentArdelyx has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Ardelyx this week, compared to 9 articles on an average week.Search InterestOnly 12 people have searched for ARDX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows7 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Ardelyx insiders have bought 426.45% more of their company's stock than they have sold. Specifically, they have bought $1,793,000.00 in company stock and sold $340,586.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Ardelyx is held by insiders.Percentage Held by Institutions58.92% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ardelyx's insider trading history. Receive ARDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter. Email Address ARDX Stock News HeadlinesArdelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions ComingAugust 5 at 4:46 PM | msn.comArdelyx, Inc. (ARDX) Q2 2025 Earnings Call TranscriptAugust 4 at 9:02 PM | seekingalpha.comGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live. | Priority Gold (Ad)Ardelyx Announces Changes to the Executive Leadership TeamAugust 4 at 4:08 PM | globenewswire.comArdelyx Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 4 at 4:01 PM | globenewswire.comPiper Sandler Maintains a Hold Rating on Ardelyx (ARDX)August 4 at 1:02 PM | msn.comArdelyx (ARDX) Projected to Post Earnings on MondayAugust 2, 2025 | americanbankingnews.comWhat to Expect from Ardelyx's EarningsAugust 1, 2025 | benzinga.comSee More Headlines ARDX Stock Analysis - Frequently Asked Questions How have ARDX shares performed this year? Ardelyx's stock was trading at $5.07 at the start of the year. Since then, ARDX shares have increased by 1.2% and is now trading at $5.13. How were Ardelyx's earnings last quarter? Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Monday, August, 4th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05. The company's revenue was up 23.0% on a year-over-year basis. Read the conference call transcript. Who are Ardelyx's major shareholders? Ardelyx's top institutional shareholders include Aberdeen Group plc (0.46%), Clay Northam Wealth Management LLC (0.14%), Harbor Capital Advisors Inc. (0.10%) and Inspire Investing LLC (0.04%). Insiders that own company stock include David M Mott, Michael Raab, Justin A Renz, Laura A Williams, Susan Rodriguez, Robert Blanks, Eric Duane Foster, Elizabeth A Grammer, Mike Kelliher, David P Rosenbaum and Robert Ora Felsch. View institutional ownership trends. How do I buy shares of Ardelyx? Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ardelyx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ardelyx investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), e.l.f. Beauty (ELF), GE Aerospace (GE), Builders FirstSource (BLDR) and ServiceNow (NOW). Company Calendar Last Earnings8/04/2025Today8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARDX CIK1437402 Webwww.ardelyx.com Phone(510) 745-1700Fax510-745-0493Employees90Year Founded2007Price Target and Rating Average Price Target for Ardelyx$11.33 High Price Target$15.00 Low Price Target$8.00 Potential Upside/Downside+120.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.14 million Net Margins-14.86% Pretax Margin-14.59% Return on Equity-34.45% Return on Assets-13.81% Debt Debt-to-Equity Ratio1.04 Current Ratio4.12 Quick Ratio3.81 Sales & Book Value Annual Sales$333.61 million Price / Sales3.68 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book7.03Miscellaneous Outstanding Shares239,260,000Free Float227,771,000Market Cap$1.23 billion OptionableOptionable Beta0.68 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:ARDX) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.